DE602005024161D1 - Peptid mit antitumoraler wirkung - Google Patents

Peptid mit antitumoraler wirkung

Info

Publication number
DE602005024161D1
DE602005024161D1 DE602005024161T DE602005024161T DE602005024161D1 DE 602005024161 D1 DE602005024161 D1 DE 602005024161D1 DE 602005024161 T DE602005024161 T DE 602005024161T DE 602005024161 T DE602005024161 T DE 602005024161T DE 602005024161 D1 DE602005024161 D1 DE 602005024161D1
Authority
DE
Germany
Prior art keywords
peptide
peptides
antitumoral effect
analogs
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005024161T
Other languages
English (en)
Inventor
Martin Jay Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Original Assignee
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University NYU filed Critical New York University NYU
Publication of DE602005024161D1 publication Critical patent/DE602005024161D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE602005024161T 2004-11-08 2005-11-04 Peptid mit antitumoraler wirkung Active DE602005024161D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62622004P 2004-11-08 2004-11-08
PCT/US2005/040078 WO2006052775A2 (en) 2004-11-08 2005-11-04 Peptide anti - tumor agent

Publications (1)

Publication Number Publication Date
DE602005024161D1 true DE602005024161D1 (de) 2010-11-25

Family

ID=36337037

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005024161T Active DE602005024161D1 (de) 2004-11-08 2005-11-04 Peptid mit antitumoraler wirkung

Country Status (7)

Country Link
US (3) US7173110B2 (de)
EP (1) EP1812035B1 (de)
JP (2) JP5138378B2 (de)
AT (1) ATE484290T1 (de)
CA (1) CA2584805C (de)
DE (1) DE602005024161D1 (de)
WO (1) WO2006052775A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173110B2 (en) * 2004-11-08 2007-02-06 New York University Peptide anti-tumor agent
JP5690810B2 (ja) * 2009-04-13 2015-03-25 イーエルシー マネージメント エルエルシー メチオニンスルホキシドペプチド、組成物および使用方法
PL2800737T3 (pl) * 2012-01-06 2020-11-02 Novus International Inc. Środki powierzchniowo czynne na bazie sulfotlenku
RU2620170C1 (ru) * 2016-08-02 2017-05-23 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России Применение катионных пептидов для индукции гибели клеток меланомы кожи человека
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
JP2022517615A (ja) * 2019-01-14 2022-03-09 ニューヨーク ユニバーシティ 環状ペプチド二量体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307082A (en) 1979-07-10 1981-12-22 New York University Method for the extraction of a factor that mediates contact inhibition of cell growth
US4530784A (en) 1983-08-19 1985-07-23 New York University Large scale extraction process for contact inhibitory factor
DE3841763A1 (de) * 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
WO2003072737A2 (en) * 2002-02-22 2003-09-04 New York University Biological inhibitions induced by contact inhibitory factor
JP2004083427A (ja) * 2002-08-23 2004-03-18 Microbial Chem Res Found 環状ヘキサペプチド及びプロテアソーム阻害剤
US7173110B2 (en) * 2004-11-08 2007-02-06 New York University Peptide anti-tumor agent

Also Published As

Publication number Publication date
CA2584805C (en) 2014-01-28
CA2584805A1 (en) 2006-05-18
JP5138378B2 (ja) 2013-02-06
US20070123454A1 (en) 2007-05-31
JP2008518622A (ja) 2008-06-05
EP1812035A2 (de) 2007-08-01
WO2006052775A3 (en) 2006-07-20
US20060258573A1 (en) 2006-11-16
EP1812035A4 (de) 2008-04-16
US7691964B2 (en) 2010-04-06
EP1812035B1 (de) 2010-10-13
JP2013005804A (ja) 2013-01-10
WO2006052775A2 (en) 2006-05-18
US20100305044A1 (en) 2010-12-02
US7173110B2 (en) 2007-02-06
ATE484290T1 (de) 2010-10-15
US8003598B2 (en) 2011-08-23

Similar Documents

Publication Publication Date Title
ATE466085T1 (de) Protease-resistente modifizierte interferon alpha polypeptide
ES2178000T3 (es) Composiciones y metodos para tratar infecciones usando analogos de indolicidina.
HRP20050585A2 (en) Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
NZ534919A (en) Bioactive keratin peptides
ATE482972T1 (de) Tgf-beta1-bindende und geträgerte peptide
HK1088840A1 (en) Stable analogs of glp-1 glp-1
DE602005024161D1 (de) Peptid mit antitumoraler wirkung
HRP20050024A2 (en) Pegylated t20 polypeptide
CY1105616T1 (el) ΠΕΠΤΙΔΙΑ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TGFβ1
DE69836199D1 (de) Anti-invasive and anti-angiogene urokinase fragmente und deren verwendung
NO20062198L (no) Bradykinin B1 reseptorantagonister
CY1116164T1 (el) Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου
CY1118930T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
DE60138558D1 (de) Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung
DE602004014145D1 (de) Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen
WO2006122162A3 (en) Use of peptides derived from the growth factor amp-18 for the treatment of mucositis
NO20060675L (no) Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider
DE60229867D1 (de) Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
RS52448B (en) ANTITUMOR PHARMACEUTICAL COMPOSITION CONTAINING SERALIZIN POLYPEPTIDE FRAGMENTS
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
UA83989C2 (ru) Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение
AU2003260452A8 (en) Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
IT1294967B1 (it) Composizione immunogenica da tlp
ES2164011B1 (es) Uso combinado de la quimiocina ip-10 y la interleucina-12 en la preparacion de composiciones para el tratamiento de tumores malignos.
WO2007101222A3 (en) Cancer treatment